

REC'D 26 AUG 2003

WIPO PCT

PL 1053311

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

August 18, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/395,662

FILING DATE: July 12, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/21549



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

M. Sias
M. SIAS
Certifying Officer

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

07-15-02 61345662 - 11772a

PTO/SB/16 (10-01)

Approved for use through 10/31/2002 OMB 0651-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

Express Mail Label No. EL 885032723 US

1c951 U.S. PTO
07/12/02PTO
60/395662
07/12/02

INVENTOR(S)				
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)		
Huazhong	Shi	Davis, CA		
Eduardo	Blumwald	Davis, CA		
<input type="checkbox"/> Additional inventors are being named on the separately numbered sheets attached hereto				
TITLE OF THE INVENTION (500 characters max)				
IMPROVED TRANSPORTERS AND THEIR USES				
CORRESPONDENCE ADDRESS				
Direct all correspondence to:				
<input checked="" type="checkbox"/> Customer Number		20350		Place Customer Number Bar Code Label here
OR		Type Customer Number here		
<input type="checkbox"/> Firm or Individual Name				
Address				
Address				
City		State	ZIP	
Country		Telephone	Fax	
ENCLOSED APPLICATION PARTS (check all that apply)				
<input checked="" type="checkbox"/> Specification Number of Pages		31	<input type="checkbox"/> CD(s), Number	
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets		5	<input type="checkbox"/> Other (specify)	
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76				
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT				
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees				
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:			20-1430	FILING FEE AMOUNT (\$) 80
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.				
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.				
<input checked="" type="checkbox"/> No.				
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:				

Respectfully submitted,
SIGNATURE

Date 7/12/02

TYPED or PRINTED NAME Kevin Bastian

REGISTRATION NO. 34,774
(if appropriate)

TELEPHONE 415-576-0200

Docket Number: 023070-127300US

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

SF 1365267 v1

Express Mail Label No. EL885032723US

Application Data Sheet

Application Information

Application number::
Filing Date:: 07/12/02
Application Type:: Provisional
Subject Matter:: Utility
Suggested classification::
Suggested Group Art Unit::
CD-ROM or CD-R??::
Number of CD disks::
Number of copies of CDs::
Sequence Submission::
Computer Readable Form (CRF)?::
Number of copies of CRF::
Title:: Improved Transporters and Their Uses
Attorney Docket Number:: 02307O-127300US
Request for Early Publication:: No
Request for Non-Publication:: No
Suggested Drawing Figure::
Total Drawing Sheets:: 5
Small Entity?:: Yes
Latin name::
Variety denomination name::
Petition included?:: No
Petition Type::
Licensed US Govt. Agency::
Contract or Grant Numbers One::
Secrecy Order in Parent Appl.: No

Applicant Information

Applicant Authority Type:: Inventor

Correspondence Information

Correspondence Customer Number:: 20350

Representative Information

Representative Customer Number:: 20350

Domestic Priority Information

Application:: Continuity Type:: Parent Application:: Parent Filing Date::

Foreign Priority Information

Country:: Application number:: Filing Date::

Assignee Information

Assignee Name:: The Regents of the University of California

Street of mailing address::

City of mailing address::

State or Province of mailing address::

Country of mailing address::

Postal or Zip Code of mailing address::

Express Mail Label No. EL885032723US
Attorney Docket No.: 023070-127300US
Client Reference No. 2002-502-1

PROVISIONAL PATENT APPLICATION

Improved Transporters and Their Uses

Inventor(s): Huazhong Shi, a citizen of China, residing at 1411 Drake Drive #2,
Davis, CA 95616

Eduardo Blumwald, a citizen of Canada, residing at 612 Jerome St.,
Davis, CA 95616

Assignee: REGENTS OF THE UNIVERSITY OF CALIFORNIA
Office of Technology Transfer
1111 Franklin Street, 5th Floor
Oakland, CA 94607

Entity: Small

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200

Express Mail Label No. EL885032723US
Attorney Docket No.: 02307O-127300US
Client Reference No. 2002-502-1

5

Improved Transporters and Their Uses

CROSS-REFERENCES TO RELATED APPLICATIONS

[01] NOT APPLICABLE

10

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[02] This invention was made with Government support under Grant No.
IBN 0110622, awarded by the National Science Foundation. The government has certain
15 rights in this invention.

FIELD OF THE INVENTION

[03] The present invention is generally related to plant genetic engineering.
In particular, the invention is directed to nucleic acids and methods for conferring salt
20 tolerance on plants and other organisms.

BACKGROUND OF THE INVENTION

[04] Environmental stress due to salinity is one of the most serious factors
limiting the productivity of agricultural crops, which are predominantly sensitive to the
25 presence of high concentrations of salts in the soil. Large terrestrial areas of the world are
affected by levels of salt inimical to plant growth. It is estimated that 35-45% of the 279
million hectares of land under irrigation is presently affected by salinity. This is exclusive of
the regions classified as arid and desert lands, (which comprise 25% of the total land of our
planet). Salinity has been an important factor in human history and in the life spans of
30 agricultural systems. Salt impinging on agricultural soils has created instability and has
frequently destroyed ancient and recent agrarian societies. The Sumerian culture faded as a
power in the ancient world due to salt accumulation in the valleys of the Euphrates and Tigris
rivers. Large areas of the Indian subcontinent have been rendered unproductive through salt

5 [05] Although there is engineering technology available to combat this problem, through drainage and supply of high quality water, these measures are extremely costly. In most of the cases, due to the increased need for extensive agriculture, neither improved irrigation efficiency nor the installation of drainage systems is applicable. Moreover, in the arid and semi-arid regions of the world water evaporation exceeds precipitation. These soils are inherently high in salt and require vast amounts of irrigation to
10 become productive. Since irrigation water contains dissolved salts and minerals, an application of water is also an application of salt that compounds the salinity problem.

[06] Increasing emphasis is being given to modify plants to fit the restrictive growing conditions imposed by salinity. If economically important crops could be manipulated and made salt resistant, this land could be farmed resulting in greater sales of seed and greater yield of useful crops. Conventional breeding for salt tolerance has been attempted for a long time. These breeding practices have been based mainly on the following strategies: a) the use of wide crosses between crop plants and their more salt-tolerant wild relatives (Rush and Epstein, *J. Amer. Hort. Sci.*, 106:699-704 (1981)), b) screening and selecting for variation within a particular phenotype (Norlyn, in *Genetic Engineering of Osmoregulation*, pp. 293-309 (1980)), c) designing new phenotypes through recurrent selection (Tal, *Plant & Soil*, 89:199-226 (1985)). The lack of success in generating tolerant varieties (given the low number of varieties released and their limited salt tolerance) (Flowers and Yeo, *Aust. J. Plant. Physiol.*, 22:875-884 (1995)) would suggest that conventional breeding practices are not enough and that in order to succeed a breeding program should include the engineering of transgenic crops (Bonhert and Jensen, *Aust. J. Plant. Physiol.*, 23:661-667 (1996)).

[07] Several biochemical pathways associated with stress tolerance have been characterized in different plants and a few of the genes involved in these processes have been identified and in some cases the possible role of proteins has been investigated in transgenic/overexpression experiments. Several compatible solutes have been proposed to play a role in osmoregulation under stress. Such compatible solutes, including carbohydrates (Tarcynski et al., *Science*, 259:508-510 (1995)), amino acids (Kishor et al., *Plant Physiol.*, 108:1387-1394 (1995)) and quaternary N-compounds (Ishtani et al., *Plant Mol. Biol.*, 27:307-317 (1995)) have been shown to increase osmoregulation under stress. Also, proteins that are

normally expressed during seed maturation (LEAs, Late Embryogenesis Abundant proteins) have been suggested to play a role in water retention and in the protection of other proteins during stress. The overexpression of LEA in rice provided a moderate benefit to the plants during water stress (Xu *et al.*, *Plant Physiol.*, 110:249-257 (1996), and Wu and Ho, WO 97/13843).

[08] A single gene (*sod2*) coding for a Na^+/H^+ antiport has been shown to confer sodium tolerance in fission yeast (Jia *et al.*, *EMBO J.*, 11:1631-1640 (1992) and Young and Zheng, WO 91/06651), although the role of this plasma membrane-bound protein appears to be only limited to yeast. One of the main disadvantages of using this gene for transformation of plants is associated with the typical problems encountered in heterologous gene expression, i.e. incorrect folding of the gene product, targeting of the protein to the target membrane and regulation of the protein function.

[09] Na^+/H^+ antiporters with vacuolar antiport activity have been identified in red beet storage tissue and a variety of halophytic and salt-tolerant glycophytic plant species (Barkla and Pantoja, *Ann. Rev. Plant. Physiol.* 47:159 (1996), and Blumwald and Gelli, *Adv. Bot. Res.* 25:401 (1997)). More recently, a gene encoding a vacuolar Na^+/H^+ antiporter from *Arabidopsis thaliana*, designated *AtNHX1*, has been isolated (Blumwald *et al.*, WO 99/47679). Overexpression of this gene in *Arabidopsis*, tomato, and canola has been shown to enhance salt tolerance in transgenic plants (Apse *et al.*, *Science*, 285:1256-1258 (1999), Zhang and Blumwald, *Nat. Biotechnol.*, 19:765-768 (2001), and Zhang *et al.*, *PNAS USA*, 98:12832-12836 (2001)).

BRIEF SUMMARY OF THE INVENTION

[10] The present invention provides methods of enhancing salt tolerance in plants by the introduction of a polynucleotide encoding a Na^+/H^+ transporter polypeptide, which when expressed confers increased salt tolerance in the plant. Each of these polypeptides have an amino acid sequence at least 80% identical to SEQ ID NO:2 and fewer than 530 amino acids.

[11] In some aspects of the invention, the method includes the introduction of a polynucleotide having a sequence consisting of SEQ ID NO: 5, 7, 9, 11, 13 or 15 to confer the salt tolerance to the plant.

[12] In some aspects of the invention the method includes the introduction of a polynucleotide encoding a polypeptide having a sequence consisting of SEQ ID NO:6, 8, 10, 12 or 14 to confer salt tolerance to the plant.

[13] In some aspects of the invention, the method includes the introduction of a polynucleotide which encodes a polypeptide of less than 500, or less than 475 amino acids in length to confer the salt tolerance to the plant.

In an alternative embodiment, the method for enhancing salt tolerance of a plant comprises introducing into the plant a polynucleotide encoding a Na⁺/H⁺ transporter polypeptide with an amino acid sequence at least 80% identical to SEQ ID NO:2 in which in the residue corresponding to the serine at position 508 in SEQ ID NO:2 is replaced by an amino acid that confers the increased salt tolerance of the Na⁺/H⁺ transporter polypeptide.

[14] In some embodiments, a neutral or polar amino acid replaces the serine at position 508 in SEQ ID NO:2.

[15] In some embodiments, the neutral or polar amino acid corresponding to the serine at position 508 in SEQ ID NO:2 is threonine, methionine, cysteine, asparagine or glutamine.

[16] In some embodiments, the purified polynucleotide sequence encoding a Na⁺/H⁺ transporter polypeptide conferring salt tolerance is SEQ ID NOS:3.

[17] In some embodiments, the Na⁺/H⁺ transporter polypeptide sequence encoded by the purified polynucleotide is SEQ ID NO:4.

[18] The present invention also provides for transgenic plants comprising a polynucleotide encoding a Na⁺/H⁺ transporter polypeptide, which when expressed confers increased salt tolerance in the plant; and wherein the transporter polypeptide comprises an amino acid sequence at least 80% identical to SEQ ID NO:2 of fewer than 530 amino acids.

[19] In some aspects of the invention, the transgenic plants comprising a Na⁺/H⁺ transporter polypeptide conferring increased salt tolerance in the plant has an amino acid sequence at least 80% identical to SEQ ID NO:2, and the residue corresponding to the serine at position 508 in SEQ ID NO:2 is replaced by an amino acid that confers the increased salt tolerance. In some aspects of the invention, the replacement amino acid is a polar or neutral amino acid, such as cysteine.

DEFINITIONS

[20] The term "plant" includes whole plants, shoot vegetative organs and/or structures (e.g. leaves, stems and tubers), roots, flowers and floral organs (e.g. bracts, sepals, petals, stamens, carpels, anthers), ovules (including egg and central cells), seed (including zygote, embryo, endosperm, and seed coat), fruit (e.g., the mature ovary), seedlings, plant tissue (e.g. vascular tissue, ground tissue, and the like), cells (e.g. guard cells, egg cells, trichomes and the like), and progeny of same. The class of plants that can be used in the

method of the invention is generally as broad as the class of higher and lower plants amenable to transformation techniques, including angiosperms (monocotyledonous and dicotyledonous plants), gymnosperms, ferns, and multicellular algae. It includes plants of a variety of ploidy levels, including aneuploid, polyploid, diploid, haploid and hemizygous.

5 [21] The phrase "nucleic acid sequence" refers to a single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. It includes chromosomal DNA, self-replicating plasmids, infectious polymers of DNA or RNA and DNA or RNA that performs a primarily structural role.

10 [22] The phrase "heterologous sequence" refers to a sequence that originates from a foreign species, or, if from the same species, is modified from its original form. For example, a promoter operably linked to a heterologous coding sequence refers to a coding sequence from a species different from that from which the promoter was derived, or, if from the same species, a coding sequence which is not naturally associated with the promoter (e.g. a genetically engineered coding sequence or an allele from a different ecotype
15 or variety).

 [23] A polynucleotide "exogenous to" an individual plant is a polynucleotide which is introduced into the plant by any means other than by a sexual cross. Examples of means by which this can be accomplished are described below, and include Agrobacterium-mediated transformation, biolistic methods, electroporation, and the like.
20 Such a plant containing the exogenous nucleic acid is referred to here as a T1 (e.g. in *Arabidopsis* by vacuum infiltration) or R0 (for plants regenerated from transformed cells in vitro) generation transgenic plant. Transgenic plants that arise from sexual cross or by selfing are descendants of such a plant.

 [24] An "*NHX1* nucleic acid" or "*NHX1* polynucleotide sequence" of the
25 invention is a subsequence or full length polynucleotide which, encodes a *NHX1* polypeptide and its complement, e.g. SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, or 15. One example of an *NHX1* gene, from *Arabidopsis*, is *AtNHX1*. The *NHX1* gene products of the invention (e.g. mRNAs or polypeptides) are characterized by the ability to confer increased salt tolerance. A *NHX1* polynucleotide of the invention typically comprises a coding sequence of at least about 250
30 nucleotides to about 2000 nucleotides in length. Usually the *NHX1* nucleic acids of the invention are from about 400 to about 1600 nucleotides.

 [25] In the expression of transgenes one of skill will recognize that the inserted polynucleotide sequence need not be identical and may be "substantially identical" to

a sequence of the gene from which it was derived. As explained below, these variants are specifically covered by this term.

[26] In the case where the inserted polynucleotide sequence is transcribed and translated to produce a functional *NHX1* polypeptide, one of skill will recognize that because of codon degeneracy, a number of polynucleotide sequences will encode the same polypeptide. These variants are specifically covered by the terms "*NHX1* polynucleotide sequence" or "*NHX1* polynucleotide sequence". In addition, the terms specifically include those full length sequences substantially identical (determined as described below) with an *NHX1* gene sequence and that encode proteins that retain the function of the encoded proteins. Thus, in the case of the *Arabidopsis AtNHX1* gene disclosed here, the above term includes variant polynucleotide sequences which have substantial identity with the sequences disclosed here and which encode proteins capable of conferring salt tolerance on a transgenic plant comprising the sequence.

[27] Two polynucleotides or polypeptides are said to be "identical" if the sequence of nucleotides or amino acid residues, respectively, in the two sequences is the same when aligned for maximum correspondence as described below. The term "complementary to" is used herein to mean that the complementary sequence is identical to all or a portion of a reference polynucleotide sequence.

[28] Sequence comparisons between two (or more) polynucleotides or polypeptides are typically performed by comparing sequences of the two sequences over a segment or "comparison window" to identify and compare local regions of sequence similarity. The segment used for purposes of comparison may be at least about 20 contiguous positions, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

[29] Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman Adv. Appl. Math. 2: 482 (1981), by the homology alignment algorithm of Needleman and Wunsch J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson and Lipman Proc. Natl. Acad. Sci. (U.S.A.) 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.), or by inspection. "Percentage of sequence identity" is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may

comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

[30] The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 60% sequence identity, preferably at least 80%, more preferably at least 90% and most preferably at least 95%, compared to a reference sequence using the programs described above (preferably BESTFIT) using standard parameters. One of skill will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 40%, preferably at least 60%, more preferably at least 90%, and most preferably at least 95%. Polypeptides which are "substantially similar" share sequences as noted above except that residue positions which are not identical may differ by conservative amino acid changes. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

[31] Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions. Stringent conditions are sequence dependent and will be different in different circumstances. Generally, stringent conditions are selected to be about 5° C. to about 20° C. lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a

perfectly matched probe. Typically, stringent conditions will be those in which the salt concentration is about 0.02 molar at pH 7 and the temperature is at least about 60° C. However, nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical.

5 This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

[32] As used herein, a homolog of a particular *NHX1* gene (e.g., the *Arabidopsis AtNHX1* genes disclosed here) is a second gene (either in the same species or in a different species) which has a polynucleotide sequence of at least 50 contiguous nucleotides

10 which are substantially identical (determined as described above) to a sequence in the first gene. It is believed that, in general, homologs share a common evolutionary past.

BRIEF DESCRIPTION OF THE DRAWINGS

[33] FIG. 1 shows yeast transformation assay results indicating modified

15 *AtNHX1* increases salt tolerance.

[34] FIG. 2 shows yeast transformation assay results showing C-terminal deletions of *AtNHX1* control Na⁺/K⁺ selectivity of the transporter.

[35] FIG. 3 shows yeast transformation assay results indicating modified

20 *AtNHX1* increases Li⁺ tolerance.

[36] FIG. 4 shows yeast transformation assay results indicating modified

AtNHX1 increases tolerance to osmotic stress.

[37] FIG. 5 shows the results of yeast transformation assays performed to characterize activity of *AtNHX1* N-terminus and transmembrane domains

25 DETAILED DESCRIPTION OF THE INVENTION

[38] The present invention provides novel modified isolated nucleic acid molecules encoding proteins for the transport of sodium ions across a membrane of a cell, for example, from the cytosol of a cell into a vacuole, to promote salt tolerance in plants.

[39] *NHX1* genes encode membrane bound Na⁺/H⁺ antiport transporters

30 that conduct Na⁺ across a membrane using an electrochemical gradient of protons, generated, for example, by vacuolar H⁺-adenosine triphosphatase (ATPase) and H⁺-inorganic pyrophosphatase (PP_{ase}). In the present invention, mutated and truncated forms of *NHX1* containing augmented transport activity have been created. The modified gene products (proteins) allow more accumulation of sodium ions from the cytosol into the intracellular

compartments, such as the vacuole, compared with the entire native protein. These genes allow for the engineering of salt tolerant plants by transformation of salt-sensitive crops overexpressing this gene.

5 [40] The invention also includes modified Na^+/H^+ antiporters having changed ion selectivity or ionic permeability leading to increased salt or drought or osmotic tolerance.

[41] The invention also relates to the modification of *NHX1* genes by using site-directed mutagenesis and deletions based on PCR amplification to screen the modified protein forms with increased transport activity or changed ion selectivity.

10

Isolation of nucleic acids of the invention

[42] Generally, the nomenclature and the laboratory procedures in recombinant DNA technology described below are those well known and commonly employed in the art. Standard techniques are used for cloning, DNA and RNA isolation, 15 amplification and purification. Generally enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like are performed according to the manufacturer's specifications. These techniques and various other techniques are generally performed according to Sambrook *et al.*, Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, (1989) or Current Protocols in 20 Molecular Biology, Volumes 1-3, John Wiley & Sons, Inc. (1994-1998).

[43] Using the sequences provided here, the isolation of *NHX1* nucleic acids may be accomplished by a number of techniques. For instance, oligonucleotide probes based on the sequences disclosed here can be used to identify the desired gene in a cDNA or genomic DNA library. To construct genomic libraries, large segments of genomic DNA are 25 generated by random fragmentation, e.g. using restriction endonucleases, and are ligated with vector DNA to form concatemers that can be packaged into the appropriate vector. To prepare a cDNA library, mRNA is isolated from the desired organ, such as flowers, and a cDNA library which contains the *NHX1* gene transcript is prepared from the mRNA. Alternatively, cDNA may be prepared from mRNA extracted from other tissues in which 30 *AtNHX1* genes or homologs are expressed.

[44] The cDNA or genomic library can then be screened using a probe based upon the sequence of a cloned *NHX1* gene or fragment thereof disclosed here. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate homologous

genes in the same or different plant species. Alternatively, antibodies raised against a *NHX1* polypeptide or fragment thereof can be used to screen a mRNA expression library.

[45] Alternatively, the nucleic acids of interest can be amplified from nucleic acid samples using amplification techniques. For instance, polymerase chain reaction (PCR) technology can be used to amplify the sequences of the *NHX1* genes directly from genomic DNA, from cDNA, from genomic libraries or cDNA libraries. PCR and other in vitro amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes. For a general overview of PCR see PCR Protocols: A Guide to Methods and Applications. (Innis, M, Gleaned, D., Sninsky, J. and White, T., eds.), Academic Press, San Diego (1990).

[46] Polynucleotides may also be synthesized by well-known techniques as described in the technical literature. See, e.g., Carruthers *et al.*, *Cold Spring Harbor Symp. Quant. Biol.*, 47:411-418 (1982), and Adams *et al.*, *J. Am. Chem. Soc.*, 105:661 (1983). Double stranded DNA fragments may then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

[47] *NHX1* nucleic acids of interest may also be identified by searching nucleic acid databases, e.g., EST databases and identifying sequences with high similarity to a known *NHX1* nucleic acid sequence. Once a candidate *NHX1* nucleic acid or polynucleotide sequence of the invention has been identified, standard methods can be used to determine if the putative nucleic acid is a *NHX1* nucleic acid of the invention. Methods of assaying for *NHX1* activity are known in the art, e.g., see example 1 and Apse *et al.*, *Science*, 285, 1256-1258.

Preparation of recombinant vectors

[48] To use isolated sequences for transformation and other molecular biological techniques, recombinant DNA vectors suitable for transformation of plant cells are prepared. Techniques for transforming a wide variety of higher plant species are well known and described in the technical and scientific literature. See, for example, Weising *et al.* *Ann. Rev. Genet.*, 22:421-477 (1988). A DNA sequence coding for the desired polypeptide, for example a cDNA sequence encoding a full length protein, will preferably be combined with transcriptional and translational initiation regulatory sequences which will direct the transcription of the sequence from the gene in the intended tissues of the transformed plant.

[49] For example, for overexpression, a plant promoter fragment may be employed which will direct expression of the gene in all tissues of a regenerated plant. Such promoters are referred to herein as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation. Examples of constitutive promoters include the cauliflower mosaic virus (CaMV) 35S transcription initiation region, the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*, and other transcription initiation regions from various plant genes known to those of skill. Such genes include for example, ACT11 from *Arabidopsis* (Huang *et al. Plant Mol. Biol.*, 33:125-139 (1996)), Cat3 from *Arabidopsis* (GenBank No. U43147, Zhong *et al., Mol. Gen. Genet.*, 251:196-203 (1996)), the gene encoding stearyl-acyl carrier protein desaturase from *Brassica napus* (Genbank No. X74782, Solcombe *et al. Plant Physiol.*, 104:1167-1176 (1994)), GPc1 from maize (GenBank No. X15596, Martinez *et al. J. Mol. Biol.*, 208:551-565 (1989)), and Gpc2 from maize (GenBank No. U45855, Manjunath *et al., Plant Mol. Biol.*, 33:97-112 (1997)).

[50] Alternatively, the plant promoter may direct expression of the *NHX1* nucleic acid in a specific tissue, organ or cell type (*i.e.* tissue-specific promoters, organ-specific promoters) or may be otherwise under more precise environmental or developmental control (*i.e.* inducible promoters). Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions, elevated temperature, the presence of light, or sprayed with chemicals/hormones. One of skill will recognize that an organ-specific promoter may drive expression of operably linked sequences in organs other than the target organ. Thus, as used herein an organ-specific promoter is one that drives expression preferentially in the target organ, but may also lead to some expression in other organs as well.

[51] A number of tissue-specific promoters can also be used in the invention. For instance, root promoters that direct expression of root tissue nucleic acids are of particular importance to the current invention.

[52] If proper polypeptide expression is desired, a polyadenylation region at the 3'-end of the coding region should be included. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA.

[53] The vector comprising the sequences (*e.g.*, promoters or coding regions) from genes of the invention will typically comprise a marker gene that confers a selectable phenotype on plant cells. For example, the marker may encode biocide resistance,

particularly antibiotic resistance, such as resistance to kanamycin, G418, bleomycin, hygromycin, or herbicide resistance, such as resistance to chlorosulfuron or Basta.

Production of transgenic plants

5 [54] DNA constructs of the invention may be introduced into the genome of the desired plant host by a variety of conventional techniques. For example, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation and microinjection of plant cell protoplasts, or the DNA constructs can be introduced directly to plant tissue using biolistics, e.g., DNA particle bombardment.

10 [55] Microinjection techniques are known in the art and well described in the scientific and patent literature. The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski *et al. Embo J.*, 3:27 17-2722 (1984). Electroporation techniques are described in Fromm *et al. Proc. Natl. Acad. Sci. USA*, 82:5824 (1985). Biolistic transformation techniques are described in Klein *et al. Nature*, 327:70-73
15 (1987).

 [56] Alternatively, the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional *Agrobacterium tumefaciens* host vector. The virulence functions of the *Agrobacterium tumefaciens* host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is
20 infected by the bacteria. *Agrobacterium tumefaciens*-mediated transformation techniques, including disarming and use of binary vectors, are well described in the scientific literature. See, for example Horsch *et al. Science*, 233:496-498 (1984), and Fraley *et al. Proc. Natl. Acad. Sci. USA*, 80:4803 (1983) and Gene Transfer to Plants, Potrykus, ed. (Springer-Verlag, Berlin 1995).

25 [57] Transformed plant cells which are derived by any of the above transformation techniques can be cultured to regenerate a whole plant which possesses the transformed genotype and thus the desired phenotype such as decreased farnesyltransferase activity. Such regeneration techniques rely on manipulation of certain phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker that has
30 been introduced together with the desired nucleotide sequences. Plant regeneration from cultured protoplasts is described in Evans *et al.*, *Protoplasts Isolation and Culture, Handbook of Plant Cell Culture*, pp. 124-176, MacMillan Publishing Company, New York, 1983; and Binding, *Regeneration of Plants, Plant Protoplasts*, pp. 21-73, CRC Press, Boca Raton, 1985. Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such

regeneration techniques are described generally in Klee *et al.*, *Ann. Rev. of Plant Phys.*, 38:467-486 (1987).

[58] The nucleic acids of the invention can be used to confer desired traits on essentially any plant. Thus, the invention has use over a broad range of plants, including
 5 species from the genera *Anacardium*, *Arachis*, *Asparagus*, *Atropa*, *Avena*, *Brassica*, *Chlamydomonas*, *Chlorella*, *Citrus*, *Citrullus*, *Capsicum*, *Carthamus*, *Cocos*, *Coffea*, *Cucumis*, *Cucurbita*, *Cyrtomium*, *Daucus*, *Elaeis*, *Fragaria*, *Glycine*, *Gossypium*, *Helianthus*, *Heterocallis*, *Hordeum*, *Hyoscyamus*, *Lactuca*, *Laminaria*, *Linum*, *Lolium*, *Lupinus*, *Lycopersicon*, *Macrocystis*, *Malus*, *Manihot*, *Majorana*, *Medicago*, *Nereocystis*, *Nicotiana*,
 10 *Olea*, *Oryza*, *Osmunda*, *Panicum*, *Pannisetum*, *Persea*, *Phaseolus*, *Pistachia*, *Pisum*, *Pyrus*, *Polypodium*, *Prunus*, *Pteridium*, *Raphanus*, *Ricinus*, *Secale*, *Senecio*, *Sinapis*, *Solanum*, *Sorghum*, *Theobromus*, *Trigonella*, *Triticum*, *Vicia*, *Vitis*, *Vigna*, and *Zea*.

[59] One of skill will recognize that after the expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other
 15 plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.

[60] Using known procedures one of skill can screen for plants of the invention by detecting the increase or decrease of *NHX1* mRNA or protein in transgenic plants. Means for detecting and quantifying mRNAs or proteins are well known in the art,
 20 e.g., Northern Blots, Western Blots or activity assays. The plants of the invention can also be identified by detecting the desired phenotype. For instance, measuring salt tolerance or drought tolerance using methods as described below.

[61] Detection of transgenic organisms of the invention

Transformed yeast strains containing the polynucleotides of the invention can
 25 be analyzed using established molecular biology techniques as well as by monitoring growth rates using culture medium selective for a wide variety of phenotypes including salt tolerance.

[62] Alternatively, transgenic plants comprising the invention may be the subject of analysis. After preparation of the expression cassettes containing the
 30 polynucleotides of the present invention and introduction of the cassettes into a plant, the resultant transgenic plants can be assayed for the phenotypical characteristics associated with increased or decreased *NHX1* expression. For example, after introduction of the cassette into a plant, the plants are screened for the presence of the transgene and crossed to an inbred or hybrid line. Progeny plants are then screened for the presence of the transgene and self-

pollinated. Progeny from the self-pollinated plants are grown. The resultant transgenic plants can be assayed for increased salt tolerance and increased drought tolerance, and decreased sensitivity to toxins. For example, a transgenic plant can be assayed for increased salt tolerance or drought tolerance. Methods for assaying for increased salt tolerance are
 5 known and include measuring the growth rate of plants at increasing salt concentrations. Plant biomass, root/shoot ratios, and tissue ion content. Root and hypocotyl growth rates can are measured and correlated with tissue water content of plants growing at different salt concentrations. Methods for assaying increased drought tolerance are also well established and include measuring transpiration rates of transgenic plant tissues, stomatal conductance,
 10 rate of water loss in a detached leaf assay or examining leaf turgor. Transgenic plants with decreased transpiration rates, for example, have increased drought tolerance.

EXAMPLES

EXAMPLE 1: SITE-DIRECTED MUTAGENESIS AND CLONING OF TRUNCATED

15 *ATNHX1*

[63] The full length cDNA of *AtNHX1* was obtained by RT-PCR and cloned into pCR2.1-TOPO vector (Invitrogen). The sequence was confirmed by sequencing the full open reading frame. The full length cDNA was then subcloned into yeast vector pYPGE15 by using BamH1 and EcoR1 cloning sites. Site-directed mutagenesis was carried
 20 out by following the instruction of QuikChange Site-Directed Mutagenesis Kit (Stratagene). The primers that were used for generation SM-23 are as follows: SM-23-F, ggagacaatttgatgactgcttcacgcgaccgctc; SM-23-R, gacgggtcgcacgaagcagtcacaaattgtctcc. For the cloning of truncated *AtNHX1*, the truncated cDNA was amplified by PCR and cloned into pYPGE15 vector. The primers for the truncated *AtNHX1* cloning are as follows: EXCH-5,
 25 agctaggtacccgatctagaagaagataacaatgttg; EXCH-DL-1, agctgaattcctagggtacaagccacgacctc; EXCH-DL-2, agctgaattcctacaagaagccacgtatactg; EXCH-DL-3, agctgaattcctaagataacatgctcgtggtg. All sequences were verified by sequencing.

EXAMPLE 2: YEAST TRANSFORMATION AND DROP TESTS

30 [64] The yeast cells were transformed using the lithium acetate/PEG method. Yeast cells were inoculated into drop-out liquid medium and cultured overnight at 30°C. The cells were harvested by centrifugation and resuspended into APG medium

(Rodriguez-Navarro and Ramos, *J. Bacteriol.*, 159:940-945 (1984)) and the OD600 was adjusted to 1.0. Serial 10 times dilutions were made and 3 μ l of the cells were loaded onto APG medium with different salt supplements, or onto YPD (1% yeast extract, 2% peptone, 2% glucose) medium with 10 mg/L hygromycin.

5

EXAMPLE 3: INCREASED SALT TOLERANCE CONFERRED BY MODIFIED *AtNHX1*

[65] As shown in FIG. 1, the yeast mutant strain (Δ ena1 Δ nhx1) lacking endogenous NHX1 Na^+/H^+ antiporter was more sensitive to NaCl as well as hygromycin than the control strain (Δ ena1). Expression of *AtNHX1* in the yeast mutant partially recovered the mutant phenotype, indicating that *AtNHX1* functions as a Na^+/H^+ antiporter to compartmentalize the Na^+ into vacuole. The modified *AtNHX1*, including SM-23, D1-1, D1-2, and D1-3, conferred yeast mutant cell more tolerance to salt and hygromycin than the complete form. This result suggests that the modified *AtNHX1* have higher antiport activity and could transport more Na^+ into the vacuole.

15

EXAMPLE 4: CHANGED ION SELECTIVITY OF MODIFIED *AtNHX1*

[66] When grown on the APG medium without NaCl, the yeast cells grew equally well regardless of the expression of complete or modified *AtNHX1* (FIG. 2). However, the yeast cells expressing modified *AtNHX1* showed higher tolerance to NaCl than those expressing the complete form of *AtNHX1*, when increased K^+ was present in the medium. This result suggests that the C-terminus of *NHX1* genes control the Na^+/K^+ selectivity.

EXAMPLE 5: INCREASED Li^+ TOLERANCE CONFERRED BY MODIFIED *AtNHX1*

[67] The yeast NHX1 can transport both Na^+ and Li^+ . The yeast mutant lacking the NHX1 gene is more sensitive to Li^+ than the control yeast strain (FIG.3). Although *AtNHX1* could rescue the Na^+ sensitive phenotype of yeast mutant (Fig. 1), *AtNHX1* was unable to restore the Li^+ sensitive phenotype of the yeast mutant as shown in figure 3, indicating that *AtNHX1* has little or no activity for Li^+ transport. Surprisingly, the yeast mutant cells expressing modified *AtNHX1* displayed Li^+ tolerance almost to the level of control yeast strain. This result provides a possibility to modify transporters capable to

25

30

detoxify different ions, and to engineer plants to be able to tolerate different toxic ions when overexpressing the modified transporters.

EXAMPLE 6: ELEVATED TOLERANCE TO OSMOTIC STRESS IN YEAST

5 EXPRESSING MODIFIED *ATNHX1*

[68] The vacuolar Na^+/H^+ antiporter can sequester Na^+ into vacuole and maintain the turgor pressure of the cell. The regulation of turgor pressure may function to drive water flow into the cell under osmotic stress. The yeast mutant cells lacking of *NHX1* showed sensitive phenotype after adding over 1M KCl to the growth medium (FIG. 4),
 10 suggesting that *NHX1* is also important in osmotic regulation. Since Na^+ was absent in the growth medium, the osmotic regulation by *NHX1* was possibly fulfilled by transport of K^+ into vacuole. Expression of complete form of *AtNHX1* could not complement the mutant phenotype, but modified forms of *AtNHX1* rescued the mutant cells growth to the level as that of the wild type (Δena1), indicating that modified forms of *AtNHX1* have higher K^+ transport
 15 activity than the complete form.

[69] It is possible to use the modified forms of *NHX1* to engineer plants to be more drought tolerance. Since the modified forms of *AtNHX1* could transport more K^+ into the vacuole, the higher concentration of K^+ in the vacuole could drive water uptake into the cell, which would generate higher strength to force more water flow through the xylem
 20 stream. Theoretically, the transgenic plants overexpressing these modified forms of *AtNHX1* could take up water more effectively, and have more tolerance to drought stress.

EXAMPLE 7: MODIFIED *NHX1*

[70] Using the methods described previously in Examples 1 and 2, modified
 25 *NHX1* polynucleotides including 23 site mutations, 3 N-terminus deletions, and 3 C-terminus deletions of *AtNHX1* cDNA were generated (See Table 1). The modified *AtNHX1* cDNAs in yeast vector were transferred into a yeast mutant lacking endogenous Na^+/H^+ antiporter *NHX1* and Na^+ pump *ENA1-4*. The activities and ion selectivity of the transformants were determined by testing the growth of yeast harboring distinct forms of *AtNHX1* under different
 30 growth conditions.

TABLE 1

Name	Mutation	Growth
Full	NA	++++
SM-1	Y85C/L86R	+
SM-2	D137C	++++
SM-3	D142C	+
SM-4	D145C	++++
SM-5	D157C	++++
SM-6	D168C/E169V	++++
SM-7	E180V	++++
SM-8	D185C	+++
SM-9	H202A	+++
SM-10	H205A	++++
SM-11	H210A	++++
SM-12	H285A	++++
SM-13	H289A	++++
SM-14	N290D	++++
SM-15	H301A	++++
SM-16	R390C	++++
SM-17	G391E	++++
SM-18	R404C	++++
SM-19	H407A	++++
SM-20	R411C	++++
SM-21	H499A	++++
SM-22	D506C/D507C	+++++
SM-23	S508C	+++++
DL-1	17 aa deletion	+++++
DL-2	47 aa deletion	+++++
DL-3	84 aa deletion	+++++
NDL-1	17 aa deletion	+++++++
NDL-2	69 aa deletion	+++
DDL-3	98 aa deletion	+++

EXAMPLE 8: CHARACTERIZATION OF ATNHX1 N-TERMINUS AND
TRANSMEMBRANE DOMAINS

- [71] The functions of the free N-terminus and the first several transmembrane domains of AtNHX1 were characterized using the methods described in
- 5 Examples 1 and 2 above. Three N-terminal deletion forms of AtNHX1 were created and analyzed in yeast complementation tests. The deletion of the free N-terminus of AtNHX1 (NDL-1, deletion of the first 17 amino acids) conferred yeast mutant strain ($\Delta ena1 \Delta nhx1$) more tolerant to hygromycin and NaCl compared with the full AtNHX1. The growth of yeast cells expressing NDL-1 was approximately 30 times higher than that expressing full
- 10 AtNHX1, indicating that the free N-terminus of AtNHX1 is a negative regulator for antiporter function in yeast cells (Fig. 5). The deletion of the first two transmembrane domains (NDL-2) and the deletion of the first three transmembrane domains (NDL-3) abolished the AtNHX1 function on some extent. These results provide the possibility to engineer plant more tolerance to salt by overexpressing modified forms of AtNHX1 with
- 15 elevated antiport activity, for instance, NDL-1.

[72] The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.

SEQUENCE LISTING

SEQ ID NO:1

Wildtype AtNHX1

1 atgttgatt cctagtgtc gaaactgcct tcgttatcga catctgatca cgcttctgtg
5 61 gttgcgttga atctctttgt tgcacttctt tgtgcttga ttgttcttgg tcactctttg
121 gaagagaata gatggatgaa cgaatccatc accgccttgt tgattgggct aggcactggg
181 gttaccattt tgttgattag taaaggaaaa agcctgcctc ttctcgtctt tagtgaagat
241 cttttctca tatatcttt gccacccatt atattcaatg cagggtttca agtaaaaaag
301 aagcagtttt tccgcaattt cgtgactatt atgcttttgg gtgctgttgg gactattatt
10 361 tcttgacaaa tcatatctct aggtgtaaca cagttcttta agaagtggga cattggaacc
421 ttgacttgg gtgattatct tgctattggg gccatatttg ctgcaacaga ttcagtatgt
481 aactgcagg ttctgaatca agacgagaca cctttgctti acagtcttgt attcggagag
541 ggtgttga atgatgcaac gtcagtgtg gtcttcaacg cgattcagag ctttgatctc
601 actcacctaa accacgaagc tgcctttcat cttcttgga acttcttga tttgttctc
15 661 ctaagtacct tgcctgggtc tgcaaccggt ctgataagtg cgtatgttat caagaagcta
721 tactttgaa ggcactcaac tgaccgagag gttgccctta tgatgcttat ggcgtatctt
781 tcttatatgc ttgctgagct ttctgactg agcggtatcc tcactgtgtt tttctgtggt
841 attgtgatgt cccattacac atggcacaat gtaacggaga gctcaagaat aacaacaaag
901 cataccttgg caactttgtc atttcttgcg gagacattta tttcttga ttgtggaatg
20 961 gatgccttgg acattgaaa gtggagatcc gtgagtga caccgggaac atcgatcgca
1021 gtgagctcaa tcctaattggg tctggtcatg gttggaagag cagcgttcgt ctttccgta
1081 tctttctat ctaacttagc caagaagaat caaagcgaga aatcaactt taacatgcag
1141 gttgtgattt ggtggtctgg tctcatgaga ggtgctgtat ctatggctct tgcatacaac
1201 aagtttcaa gggccgggca cacagatga cgcgggaatg caatcatgat cagagtagc
25 1261 ataactgtct gctttttag cacagtgggt tttggtatgc tgaccaaacc actcataagc
1321 tccattatc cgcaccagaa cgcaccacg agcatgttat ctgatgcaa caccctaaaa
1381 tccatacata tccctttgtt ggaccaagac tcttcatgt agccttcagg gaaccacaat
1441 gtgcctcggc ctgacagtat acgtggcttc ttgacacggc ccactgaac cgtgcattac
1501 tactggagac aattgatga ctcttcatg cgacccgtct ttggaggtcg tggctttgta
30 1561 cctttgttc caggttctcc aactgagaga aacctctctg atcttagtaa ggct

SEQ ID NO:2

Wildtype AtNHX1, protein sequence

MLDSLVS KLPSLSTSDHASVVALNLFVALLCACIVLGHLLLEENR
35 WMNESITALLIGLGTGVTILLISKGKSSHLLVFSEDLFFTYLLPPIIFNAGFQVKKKQ
FFRNFVTIMLFGAVGTIISCTIISLGVTQFFKKLDIGTFDLGDYLAIGAIFAATDSVC
TLQVLNQDETPLLYSLVFGEVGVNDATSVVVFNAIQSFDLTHLNHEAAFHLLGNFLY
LFLSTLLGAATGLISAYVIKKLYFGRHSTDREVALMMLMAYLSYMLAELFDLSGIL
TVFFCGIVMSHYTWHNVTESSRITTKHTFATLSFLAETFIFLYVGMDALDIDKWRVS
40 DTPGTSIAVSSILMGLVMVGRAAFVFLSFLSNLAKKNQSEKINFNMQVVIWWSGLM
RGAVSMALAYNKFTRAGHTDVRGNAMITSTITVCLFSTVVFVGM LTKPLISYLLPHQ
NATTSMLSDDNTPKSIHIPLLDQDSFIEPSGNHNVPRPDSIRGFLTRPTRTVHYYWRQF
DDS FMRPVFGGRGFVPFVPGSPTERNPPDLSKA

SEQ ID NO:3

SM-23, S508C, single nucleic acid change, cDNA sequence

atgttggattcttagtgtcgaaactgccttcgttatcgacatcgaicacgcttctgtggtgcgtigaatctcttgt
tgcacttcttctgcttgaattgttcttggtcatctttggaagagaatagatggatgaacgaatccatcaccgccttgt
5 tgaattgggctaggcactgggtgtaccattttgtgattagtaaaggaaaaagctcgcatcttctcgtcttagtgaagat
ctttcttcatatcttttgcacccattatattcaatgcagggttcaagtaaaaaagaagcagttttccgcaattt
cgtgactaattatgcttttgggtgctgttgggactatttcttgcacaatcatactctaggtgaacacagttcttta
agaagtggacattggaacctttgacttgggtgattatcttctatttggccatatttgcgcaacagattcagtatgt
acactgcagggttctgaatcaagacgagacaccttgccttacagcttcttattcggagagggtgtgtgaatgatgcaac
10 gtcagttgtggtcttcaacgcgattcagagcttgaicacactcacctaaaccacgaagctgctttcatcttcttgaa
acttctgtatttgttctcctaagtaccttgccttgggtgctgcaaccggctgataagtgcgtatgttatcaagaagcta
tactttggaaggcactcaactgaccgagagggtgcccttatgatgcttatggcgtatcttcttatatgcttgcagct
tttcgactgagcgggtatcctcactgtgttttctgtggtattgtgatgtccattacacatggcacaatgtaacggaga
gctcaagaataacaacaagcataaccttgcaccttgcatttcttgcggagacatttttcttctgtatgttgaatg
15 gatgccttggacattgacaagtgagatccgtgagtgacacaccgggaacatcgatcgagtgagctcaatcctaagg
tctggtcatggttgaagagcagcgttcttccgttatcgttctatctaacttagccaagaagaatcaaaagcgaga
aaatcaactttaacatgcagggttgatttgggtgctgctcatgagagggtgtatctatggctcttgcatacaac
aagtttacaaggcgccgggcacacagatgtacgcgggaatgcaatcatgatcacgagtagataactgtctgtcttttag
cacagtgggttgggtatgctgaccaaaccactcataagctacctattaccgcaccagaacgccaccacgagcatgttat
20 ctgatgacaacaccccaaaatccatacatatcccttgggtgaccaagactcgttcattgagccttcagggaaccacaat
gtgcctcggcctgacagtatactgtgcttctgacacggccactcgaaccgtgcattactactggagacaatttgatga
ctGcttcatgcgacccgtcttggagggtcgtggcttgtacccttgttcagggttccaactgagagaaacctcctg
atcttagtaaggct

25 SEQ ID NO:4

SM-23, S508C, SINGLE AMINO ACID SUBSTITUTION, PROTEIN SEQUENCE

MLDSLVS KLPSLSTSDHASVVALNLFVALLCACIVLGHLLLEENRWMNESITALLIGLTGVTILLISKGKSSHLLVFSED
 LFFIYLLPPIFNAGFQVKKQFFRNFTIMLFGAVGTIISCTIISLGVTFKKLDIGTFDLGDYLAIGAIFAATDSVC
 TLQVLNQDETPLLYSLVFGEGVNDATSVVVFNAIQSFDLTHLNHEAAFHLLGNFLYLFLSTLLGAATGLISAYVIKKL
 5 YFGRHSTDREVALMMLMAYLSYMLAELFDLSGILTVFFCGIVMSHYTWHNVTESSRITTKHTFATLSFLAETFFLYVGM
 DALDIDK WRSVSDTPGTSIAVSSILMGLVMVGRAAFVFPFLSFLSNLAKKNQSEKINFNMQVVIWWSGLMRGAVSMALAYN
 KFTRAGHTDVRGNAIMITTITVCLFSTVVFGLTKPLISYLLPHQNATTSMLSDDNTPKSIHIPLLDQDSFIEPSGNHN
 VPRPDSIRGFLTRPTRTVHYWRQFDDCFMRPVFGGRGFVPFVPGSPTERNPPDLSKA
 ↑

10 SEQ ID NO:5

DL-1, 17 amino acids deletion from C-terminus, cDNA sequence

ATGTTGGATTCTCTAGTGTGCGAACTGCCTTCGTTATCGACATCTGATCACGCTTC
 TGTGGTTGCGTTGAATCTCTTTGTTGCACTTCTTTGTGCTTGTATTGTTCTTGGTCA
 15 TCTTTTGAAGAGAATAGATGGATGAACGAATCCATCACCGCCTTGTTGATTGGG
 CTAGGCACTGGTGTTACCATTTTGTGATTAGTAAAGGAAAAAGCTCGCATCTTC
 TCGTCTTTAGTGAAGATCTTTTCTTCATATATCTTTTGCCACCCATTATATTCAATG
 CAGGGTTTCAAGTAAAAAAGAAGCAGTTTTTCCGCAATTTCTGACTATTATGCT
 TTTTGGTGCTGTTGGGACTATTATTTCTTGACAATCATATCTCTAGGTGTAACAC
 20 AGTTCTTTAAGAAGTTGGACATTGGAACCTTTGACTTGGGTGATTATCTTGCTATT
 GGTGCCATATTTGCTGCAACAGATTGAGTATGTACACTGCAGGTTCTGAATCAAG
 ACGAGACACCTTTGCTTTACAGTCTTGTATTTCGGAGAGGGTGTGTGAATGATGC
 AACGTCAGTTGTGGTCTTCAACGCGATTGAGAGCTTTGATCTCACTCACCTAAAC
 CACGAAGCTGCTTTTCATCTTCTTGAAACTTCTTGTATTTGTTTCTCCTAAGTAC
 25 CTTGCTTGGTGCTGCAACCGGTCTGATAAGTGCGTATGTTATCAAGAAGCTA
 TACTTTGGAAGGCACTCAACTGACCGAGAGGTTGCCCTTATGATGCTTATGGCGT
 ATCTTTCTTATATGCTTGCTGAGCTTTTCGACTTGAGCGGTATCCTCACTGTGTTTT
 TCTGTGGTATTGTGATGTCCATTACACATGGCACAATGTAACGGAGAGCTCAAG
 AATAACAACAAAGCATACCTTTGCAACTTTGTCATTTCTTGCGGAGACATTTATTT

TCTTGTATGTTGGAATGGATGCCTTGGACATTGACAAGTGGAGATCCGTGAGTGA
 CACACCGGGAACATCGATCGCAGTGAGCTCAATCCTAATGGGTCTGGTCATGGTT
 GGAAGAGCAGCGTTCGTCTTTCCGTTATCGTTTCTATCTAACTTAGCCAAGAAGA
 ATCAAAGCGAGAAAATCAACTTTAACATGCAGGTTGTGATTTGGTGGTCTGGTCT
 5 CATGAGAGGTGCTGTATCTATGGCTCTTGCATACAACAAGTTTACAAGGGCCGGG
 CACACAGATGTACGCGGGAATGCAATCATGATCACGAGTACGATAACTGTCTGT
 CTTTTTAGCACAGTGGTGTGTTGGTATGCTGACCAAACCACTCATAAGCTACCTATT
 ACCGCACCAGAACGCCACCACGAGCATGTTATCTGATGACAACACCCCAAAATC
 CATACATATCCCTTTGTTGGACCAAGACTCGTTCATTGAGCCTTCAGGGAACCAC
 10 AATGTGCCTCGGCCTGACAGTATACGTGGCTTCTTGACACGGCCCACTCGAACCG
 TGCATTACTACTGGAGACAATTTGATGACTCCTTCATGCGACCCGTCTTTGGAGG
 TCGTGGCTTTGTACCC

SEQ ID NO:6

15 DL-1, 17 AMINO ACIDS DELETION FROM C-TERMINUS, PROTEIN SEQUENCE
 MLDSLVS KLPSLSTSDHASVVALNLFVALLCACIVLGHLLEENRWMNESITALLIGLG
 TGV TILLISKGKSSHLLVFSEDLFFIYLLPPIIFNAGFQVKKKQFFRNFTIMLFGAVGTI
 ISCTIISLGVTQFFKKLDIGTFDLGDYLAIGAIFAATDSVCTLQVLNQDETPLL YSLVFG
 EGVVNDATSVVVFNAIQSFDLTHLNHEAAFHLLGNFLYLFLSTLLGAATGLISAYVI
 20 KKLYFGRHSTDREVALMMLMAYLSYMLAELFDLSGILTVFFCGIVMSHYTWHNVTE
 SSRITTKHTFATLSFLAETFIFLYVGMDALDIDKWRVSVDTPGTSIAVSSILMGLVMVG
 RAAVFVPLSFLSNLAKKNQSEKINFNMQVVIWWSGLMRGAVSMALAYNKFTRAGH
 TDVRGNAIMITSTITVCLFSTVVFGMLTKPLISYLLPHQNATTSMLSDDNTPKSIHIPLL
 DQDSFIEPSGNHNVP RPDSIRGFLTRPTRTVHYYWRQFDDSFMRPVFGGRGFVP

25

SEQ ID NO:7

DL-2, 47 AMINO ACIDS DELETION FROM C-TERMINUS, CDNA SEQUENCE

atgttgattctctagtgicgaaactgccttcgttatcgacatctgatcacgcttctgtggtgcgtgaatctcttgt
 tgcacttcttctgtctgtattgttcttggtcatcttttgaagagaatagatggatgaacgaatccatcaccgccttgt
 tgattgggctaggcactgggtgtaccatttgtgattagtaaaggaaaaagctcgcattctcgtctttagtgaagat
 5 ctttctcatatatctttgccacccattatcaatgcagggttcaagtaaaaaagaagcagttttccgcaatt
 cgtgactattatgcttttgggtgtgttgggactattttcttgcaaatcatactctaggtgaacacagtcttta
 agaagttggacattggaaccttgaacttgggtgattatctgctattgggtccatatttgcgaacagattcagtatgt
 acactgcaggttctgaatcaagacgagacaccttgccttacagcttgcattcggagagggtgtgtgaatgatgcaac
 gtcagttgtgtcttcaacgcgattcagagcttgcattcactcacctaaaccacgaagctgctttcatcttcttgaa
 10 acttctgtattgtttctcctaagtaaccttgccttgggtgctgcaaccggctgataagtcgctatgtatcaagaagcta
 tactttggaaggcactcaactgaccgagagggtgcccttatgatgcttatggcgtatcttcttatatgcttgcagct
 ttgcacttgagcgggtatcctcactgtgtttctgtggtattgtgatgtccattacatggcacaatgtaacggaga
 gctcaagaataacaacaagcataaccttgcacatttgcatttctgcggagacatttttctgtatgttggatg
 gatgccttggacattgacaagtggagatccgtgagtgcacacccgggaacatcgatcgagtgagctcaatcctaagg
 15 tctggtcatggttgaagagcagcggttcttccgttatcggttctatctaacttagccaagaagaatcaaagcgaga
 aaatcaacttaacatgcaggttgatttgggtgtgtctcatgagaggtgctgtatctatggctcttgatacaac
 aagttacaaggccgggcacacagatgtacgcgggaatgcaatcatgatcacgagtagataactgtctgtcttttag
 cacagtggtgttggatgctgaccaaaccataagctacattaccgcaccagaacgccaccacgagcatgttat
 ctgatgacaacaccccaaaatccatacatatcccttgggaccaagactcgttcattgagccttcagggaaccacaat
 20 gtgcctcggcctgacagtatacgtggctcttg

SEQ ID NO:8

DL-2, 47 AMINO ACIDS DELETION FROM C-TERMINUS, PROTEIN SEQUENCE

MLDSLVS KLPSLSTSDHASVVALNLFVALLCACIVLGHLLEENRWMNESITALLIGLG
 25 TGV TILLISKGKSSHLLVFSEDLFFIYLLPPIFNAGFQVKKKQFFRN FVTIMLFGAVGTI
 ISCTIISLGVTQFFKKLDIGTFDLGDYLAIGAIFAATDSVCTLQVLNQDETPLLYSLVFG

EGVVNDATSVVVFNAIQSFDLTHLNHEAAFHLLGNFLYLFLSTLLGAATGLISAYVI
 KKLYFGRHSTDREVALMMLMAYLSYMLAELFDLSGILTVFFCGIVMSHYTWHNVTE
 SSRITTKHTFATLSFLAETFIFLYVGM DALDIDK WRSVSDTPGTSIAVSSILMGLVMVG
 RAAFVFP LSF LSNLAKKNQSEKINFMQVVIWWSGLMRGAVSMALAYNKFTRAGH
 5 TDVRGNAIMITSTITVCLFSTVVF GMLTKPLISYLLPHQNATTSM L SDDNTPKSIHIPLL
 DQDSFIEPSGNHNVP RPD SIRGFL

SEQ ID NO:9

DL-3, 84 AMINO ACIDS DELETION FROM C-TERMINUS, CDNA SEQUENCE

10 atgttgattctciagtgcgaaactgccttcgtatcgacatctgatcacgcttctgtggtgcgtgaatctcttgt
 tgcacttcttctgtctgtattgttcttggatcatctttggaagagaatagatggatgaacgaatccatcacgccttgt
 tgattgggctaggcactggtgttaccatttggtagtagtaaggaaaaagctgcactctctctgtcttagtgaagat
 ctttctcatatctcttccaccattatattcaatgcagggttcaagtaaaaaagaagcagttttccgcaattt
 cgtgactattatgcttttgggtgctgttgggactatttcttgcacaatcatctctaggtgtaacacagttcttta
 15 agaagttggacattggaaccttgcacttgggtgattatcttctattggtgccatattgctgcaacagattcagtagt
 acactgcagggttctgaatcaagacgagacaccttgccttacagtcttattcgagagggtgtgtgaatgatgcaac
 gtgagttgtgtcttcaacgcgattcagagcttgcactcactcacctaaaccacgaagctgctttcatcttctggaa
 acttctgtatttcttccctaaaglaccttgccttgggtgctgcaaccggtctgataagtcgtatgtatcaagaagcta
 tacttggaaaggcactcaactgaccgagaggttgccttatgatgcttatggcgtatcttcttatatgcttgcgtgagct
 20 ttgcacttgagcgggtatcctcactgtgttttctgtgtattgtgatgtccattacacatggcacaatgtaacggaga
 gctcaagaataacaacaaagcataccttgcacttgccttcttgcggagacatttttctgtatgttggaatg
 gatgccttggacattgacaagtggagatccgtgagtgacacaccgggaacatcgatcgagtgagctcaatcctaaggg
 tctggcatggttgaagagcagcgttcttccgttatcgttctatctaacttagccaagaagaatcaagcgaga
 aaatcaactttaacatgcaggttgtgatttgggtgctggtctcatgagaggtgctgtatctatggcttgcatacaac
 25 aagttacaaggccgggcacacagatgtacgagggaatgcaatcatgatcacgagtagataactgtctgtcttttag
 cacagtgggtgttggtatgctgaccaaacacacataagctacattaccgcaccagaacgccaccacgagcatgttat

ct

SEQ ID NO:10

DL-3, 84 AMINO ACIDS DELETION FROM C-TERMINUS, PROTEIN SEQUENCE

5 MLDSLVS KLPSLSTSDHASVVALNLFVALLCACIVLGHLLEENRWMNESITALLIGLG
TGV TILLISK GKSSHLLV FSEDLFFIYLLPPIIFNAGFQVKKKQFFRN FVTIMLFGAVGTI
ISCTIISLGVTQFFKKLDIGTFDLGDYLAIGAIFAATDSVCTLQVLNQDETPLLYSLVFG
EGVVNDATSVVVFNAIQSFDLTHLNHEAAFHLLGNFLYLFLSTLLGAATGLISAYVI
KKLYFGRHSTDREVALMMLMAYLSYMLAELFDLSGILTVFFCGIVMSHYTWHNVTE
10 SSRITTKHTFATLSFLAETFIFLYVGMDALDIDK WRSVSDTPGTSIAVSSILMGLVMVG
RAAFVFP LSF LSNLAKKNQSEKINFNMQVVIWWSGLMRGAVSMALAYNKFTRAGH
TDVRGNAIMITSTITVCLFSTVVF GMLTKPLISYLLPHQNATTSMLS

SEQ ID NO:11

15

NDL-1 cDNA sequence

atggcttctgtggtgcgtgaatcctttgtgcactctttgtcctgtattgttcttggtcatctttggaagagaa
tagatggatgaacgaatccatcaccgccttggtgattggcctaggcactggtgtaccattttgtgattagtaaggaa
20 aaagctcgcatcttctgtcttagtgaaatcctttctcatatcttttgcaccattatattcaatgcagggtt
caagtaaaaaagaagcagttttccgcaattctgactattatgccttttgggtgctgttgggactattattctgcac
aatcatatctctaggtgaacacagttcttaagaagttggacattggaaccttgactgggtgattatctgctattg
gtgccatattgtgcaacagattcagtatgtacactgcaggtctgaatcaagacgagacaccttgctttacagtctt
gtattcggagagggtgttgatgatgaacgtcagttgtggtctcaacgcgattcagagcittgatctcactcacct
25 aaaccacgaagctgttctctcttggaaactctgtattgttctcctaagtaccttgcttggtgctgcaaccg
gtctgataagtgcgtatgtatcaagaagctatacttggaggcactcaactgaccgagaggttgcccttatgatgct
atggcgatcttcttctatgctgtgagcttttcgactgagcgggtatcctcactgtgttttctgtgattgtgat
gtccattacacatggcacaatgtaacggagagctcaagaataacaacaaagcataaccttgcaacttgcatttctg
cggagacatttatttctgtatgttggaatggatgccttgacattgacaagtgagatccgtgagtgacacaccggga
30 acatcgatcgagtgagctaatcctaattgggtctggtcatggttggaagagcagcgttcgtcttccgttatcgtttct
atctaactagccaagaagaatcaaacgagaaaatcaacttaacatgcaggtgtgatttggtggtctggtctcatga
gaggtgctgtatctatggctcttgcatacaacaagttacaaggccgggcacacagatgtacgcgggaatgcaatcatg
atcacgagtacgataactgtctgtcttttagcacagtggtgttggtatgctgacaaaccactcataagctacatt
accgcaccagaacgccaccacgagcatgtatctgatgacaacccccaaaatccatacatatcccttggtagcaag
35 actggtcattgagcctcagggaaaccacaatgtgcctcggcctgacagtatacgtggtcttgacacggccactcga
accgtgcattactactggagacaattgatgactcctcatgcaccgctcttgagggtcgtggttgtacccttgt
tccaggttctccaactgagagaaccctctgatcttagtaaggct

SEQ ID NO:12

NDL-1 protein sequence

5 MASVVALNLFVALLCACIVLGHLLLEENRWMNESITALLIGLGTGVTILLISKGKSSHL
LVFSEDLFFIYLLPPIIFNAGFQVKKKQFFRNFTIMLFGAVGTIISCTIISLGVTFQFFKK
LDIGTFDLGDYLAIGAIFAATDSVCTLQVLNQDETPLLYSLVFGEVGVNDATSVVVF
NAIQSFDLTHLNHEAAFHLLGNFLYLFLSLTLLGAATGLISAYVIKKLYFGRHSTDRE
VALMMLMAYLSYMLAELFDLSGILTVFFCGIVMSHYTWHNVTESSRITTKHTFATLS
10 FLAETFIYLVGMDALDIDKWRVSVDTPGTSIAVSSILMGLVMVGRAAFVPLSFLSN
LAKKNQSEKINFNMQVVIWWSGLMRGAVSMALAYNKFTRAGHTDVRGNAIMITSTI
TVCLFSTVVFGLTKPLISYLLPHQNATTSMLSDDNTPKSIHIPLLDQDSFIEPSGNHN
VPRPDSIRGFLTRPRTVHYWRQFDDSFMRPVFGGRGFVPFVPGSPTERNPPDLSKA

15 SEQ ID NO:13

NDL-2 cDNA sequence

atgaaaagctcgcattctctgctttagtgaagatctttctcatatctttgccaccattatattcaatgcagg
gtttcaagtaaaaaagaagcagttttccgaatttcgtgactattatgcttttggtgctgtgggactattattctt
gcacaatcatatctctaggtgaacacagttcttaagaagttggacattggaaccttgacttgggtgattatcttgc
20 attggtgccatatttgcgaacagattcagtgatgtacactgcaggttctgaatcaagacgagacaccttgccttacag
tctgtattcggagaggggtgttgatgatgaacgtcagttgtggtctcaacgcgattcagagcttgcctcactc
acctaaccacgaagctgctttcatctcttggaaactctgtattgtttctcctaagcttgccttgggtgctgca
accggctgataagtgctgatgttatacaagaagctatacttggaaagcactcaactgaccgagaggttgccttatgat
gcttatggcgatcttcttatatgcttgcgtgagcttttcgacttgagcggtatccctcactgtttttctgtgattg
25 tgatgtccattacacatggcacaatgaacggagagctcaagaataacaacaagcataccttgcactttgtcattl
cttgcggagacatttatttctgtatgttggaatggatgccttgacattgacaagtggagatccgtgagtgacacacc
gggaacatcgcagtgagctcaatccaatgggtctggtcattggttggagagcagcgttcttcttccgtatcgt
ttctatctaacttaagccaagaagaatcaaacgcgagaaaatcaacttaacatgcaggttgatttgggtggtcgtc
atgagaggtgctgtatctatggctctgcatacaacaagttacaaggcgccgggcacacagatgtacgcgggaatgcaat
30 catgatcacgagtagataactgtctgtcttttagcacagtggtgttggtatgctgaccaaaccactcataagctacc
tattaccgcaccagaacgccaccacgagcatgttatctgatgacaacaccccaaatccatacatccctttgtggac
caagactcgttcattgagccttcagggaaccacaatgtgcctcggcctgacagtatactggcttcttgacacggccac
tcgaaccgtgcattactactggagacaatttgatgactcctcatgcgacccgctttggaggtcgtggctttagacct
ttgttcagggttctcaactgagagaacccctctgactttagtaaggct

35

SEQ ID NO:14

NDL-2 protein sequence

40 MKSSHLLVFSEDLFFIYLLPPIIFNAGFQVKKKQFFRNFTIMLFGAVGTIISCTIISLGV
TQFFKKLDIGTFDLGDYLAIGAIFAATDSVCTLQVLNQDETPLLYSLVFGEVGVNDAT
SVVVFNAIQSFDLTHLNHEAAFHLLGNFLYLFLSLTLLGAATGLISAYVIKKLYFGRH
STDREVALMMLMAYLSYMLAELFDLSGILTVFFCGIVMSHYTWHNVTESSRITTKHT
FATLSFLAETFIYLVGMDALDIDKWRVSVDTPGTSIAVSSILMGLVMVGRAAFVPL
SFLSNLAKKNQSEKINFNMQVVIWWSGLMRGAVSMALAYNKFTRAGHTDVRGNAI
45 MITSTITVCLFSTVVFGLTKPLISYLLPHQNATTSMLSDDNTPKSIHIPLLDQDSFIEPS
GNHNVPRPDSIRGFLTRPRTVHYWRQFDDSFMRPVFGGRGFVPFVPGSPTERNPP
DLSKA

50 SEQ ID NO:15

NDL-3 cDNA sequence

atgaaaaagaagcaggttttcgcaattcgtgactattatgcttttgggtgctgtgggactattattcttcacaaat
 catatctctaggtgaacacagttcttaagaagttggacattggaacctttgacttgggtgattatcttgcatttgggt
 5 ccataattgctgcaacagattcagtagtacactgcaggttctgaatcaagacgagacacctttgctttacagtccttga
 ttccgagagggtgttgatgatgcaacgtcagttgtgtcttcaacgcgaltcagagctttgatctcactcacctaaa
 ccacgaagctgtctttcatcttcttggaaactcttctgatttgtttctcctaagtaccttgcttgggtgctgcaaccggct
 tgataagtgctgtatgtatcaagaagctatactttggaaggcactcaactgaccgagaggttgccttatgatgcttatg
 gcgtatctttctatagcttgcgtgagcttttcgacttgcggtatcctcactgtgttttctgtgtattgtgatgtc
 10 ccattacacatggcacaatgtaacggagagctcaagaataacaacaaagcatacctttgcaacttgcatttcttgcgg
 agacatttatttctgtatgttggatggatgccttggacattgacaagtggagatccgtgagtgacacaccgggaaca
 tcgatcgagtgagctcaatcctaattgggtctgtgcatgttggagagcagcggttcgtcttccgttatcgtttatc
 taacttagccaagaagaatcaaaagcgagaaaatcaactttaacatgcaggttgtgatttgggtgtgtctcatgagag
 gtgctgtatctatggctcttgcatacaacaagtttacaagggccgggcacacagatgtacgcgggaatgcaatcatgatc
 15 acgagtacgataactgtctgtcttttagcacagtgggtgttggatgtgaccaaaccactcataagctacctattacc
 gcaccagaacgccaccacgagcatgttatctgatgacaacaccccaaatccatacatatcccttgggaccaagact
 cgttcattgagccttcagggaaccacaatgtgcctcggcctgacagtatacgttgcttcttgacacggccactcgaacc
 gtgcattactactggagacaattgatgactcctcatgcgacccgtcttggaggtcgtggcttgtacccttgttcc
 20 aggttctccaactgagagaaacctcctgatcttagtaaggct

SEQ ID NO:16

NDL-3 protein sequence

25 MKKKQFFRNFTIMLFGAVGTIISCTIISLGVTVQFFKKLDIGTFDLGDYLAIGAIFAATD
 SVCTLQVLNQDETPLYSLVFGGTVVNDATSVVVFNAIQSFDLTHLNHEAAFHLLGN
 FLYLFLSTLLGAATGLISAYVIKKLYFGRHSTDREVALMMLMAYLSYMLAELFDLS
 GILTVFFCGIVMSHYTWHNVTESSRITTKHTFATLSFLAETFIFLYVGM DALDIDKWR
 SVSDTPGTSIAVSSILMGLVMVGRAAFVFP LSFSLNLA KKNQSEKINFNMQVVIWWS
 30 GLMRGAVSMALAYNKFTRAGHTDVRGNAIMITSTITVCLFSTVVF GMLTKPLISYLL
 PHQNATTSMLSDDNTPKSIHIPLLDQDSFIEPSGNHNVPRPDSIRGFLTRPTRTVHYVW
 RQFDDSFMRPVFGGRGFVPFVPGSPTERNPPDLSKA

35

1 WHAT IS CLAIMED IS:

- 2 1. A method for enhancing salt tolerance of a plant, the method
3 comprising,
4 a. introducing into the plant a polynucleotide encoding a Na⁺/H⁺
5 transporter polypeptide, which when expressed confers increased salt tolerance in the plant;
6 and wherein the transporter polypeptide comprises:
7 i. an amino acid sequence at least 80% identical to SEQ ID NO:2;
8 and
9 ii. fewer than 530 amino acids; and
10 b. selecting a plant with enhanced salt tolerance compared to a plant
11 where the polynucleotide was not introduced.
- 1 2. The method of claim 1 wherein the polynucleotide is SEQ ID NO:5 or
2 SEQ ID NO:11.
- 1 3. The method of claim 1 wherein the polypeptide conferring salt
2 tolerance is SEQ ID NO:6 or SEQ ID NO:12.
- 1 4. The method of claim 1 wherein the polynucleotide is SEQ ID NO:7 or
2 SEQ ID NO:13.
- 1 5. The method of claim 1 wherein the polypeptide conferring salt
2 tolerance is fewer than 500 amino acids.
- 1 6. The method of claim 1 wherein the polypeptide conferring salt
2 tolerance is SEQ ID NO:8 or SEQ ID NO:14.
- 1 7. The method of claim 1 wherein the polynucleotide is SEQ ID NO:9 or
2 SEQ ID NO:15.
- 1 8. The method of claim 1 wherein the polypeptide conferring salt
2 tolerance is fewer than 475 amino acids.
- 1 9. The method of claim 1 wherein the polypeptide conferring salt
2 tolerance is SEQ ID NO:10.
- 1 10. A method for enhancing salt tolerance of a plant, the method
2 comprising,

3 a. introducing into the plant a polynucleotide encoding a Na⁺/H⁺
4 transporter polypeptide, which when expressed confers increased salt tolerance in the plant;
5 and wherein the transporter polypeptide comprises:
6 i. an amino acid sequence at least 80% identical to SEQ ID NO:2;
7 and
8 ii. wherein the residue corresponding to the serine at position 508
9 in SEQ ID NO:2 is replaced by an amino acid that confers the increased salt tolerance of the
10 Na⁺/H⁺ transporter polypeptide; and
11 b. selecting a plant with enhanced salt tolerance compared to a plant
12 where the polynucleotide was not introduced.

1 11. The method according to claim 10 wherein the amino acid that
2 replaces the serine at position 508 is a neutral polar amino acid.

1 12. The method according to claim 10 wherein the amino acid that
2 replaces the serine at position 508 is selected from the group consisting of threonine,
3 methionine, cysteine, asparagine and glutamine.

1 13. The method according to claim 10 wherein the amino acid that
2 replaces the serine at position 508 is cysteine.

1 14. A purified polynucleotide comprising a nucleotide sequence encoding
2 a Na⁺/H⁺ transporter polypeptide which when expressed confers increased salt tolerance in a
3 plant; wherein the transporter polypeptide comprises:

4 i. an amino acid sequence at least 80% identical to SEQ ID NO:2;
5 and
6 ii. fewer than 522 amino acids.

1 15. The polynucleotide of claim 14 wherein the nucleotide sequence is
2 selected from the group consisting of SEQ ID NOS:5, 7, 9, 11, 13 and 15.

1 16. The polypeptide of claim 14 wherein the amino acid sequence is
2 selected from the group consisting of SEQ ID NOS:6, 8, 10, 12, 14 and 16.

1 17. The polynucleotide according to claim 10, wherein the nucleotide
2 sequence is SEQ ID NO:3.

1 18. The polypeptide according to claim 10, wherein the amino acid
2 sequence is SEQ ID NO:4.

3

1 19. A transgenic or mutagenized plant comprising a polynucleotide
2 encoding a Na⁺/H⁺ transporter polypeptide, which when expressed confers increased salt
3 tolerance in the plant; and wherein the transporter polypeptide comprises an amino acid
4 sequence at least 80% identical to SEQ ID NO:2 of fewer than 530 amino acids.

5
1 20. A transgenic or mutagenized plant comprising a polynucleotide
2 encoding a Na⁺/H⁺ transporter polypeptide, which when expressed confers increased salt
3 tolerance in the plant; and wherein the transporter polypeptide comprises an amino acid
4 sequence at least 80% identical to SEQ ID NO:2; and
5 wherein the residue corresponding to the serine at position 508 in SEQ ID
6 NO:2 is replaced by an amino acid that confers the increased salt tolerance

EL885032723US

Express Mail Label No. EL885032723US
Attorney Docket No.: 02307O-127300US
Client Reference No. 2002-502-1

Improved Transporters and Their Uses

ABSTRACT OF THE DISCLOSURE

The present invention is generally related to plant genetic engineering. In particular, the invention is directed to nucleic acids and methods for conferring salt tolerance on plants and other organisms.

SF 1365202 v1

FIG. 2






FIG. 3




00355662.001202

FIG. 4



60395602 .001202

FIG. 5



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.